Belnacasan for COVID-19: real-time analysis

Download Image

Post

c19early.org

Belnacasan for COVID-19

1 study with 31 patients

No significant improvements are seen in meta-analysis to date.

COVID-19 Belnacasan studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−34%

RCTs (1)−34%

Early (1)−34%

00.511.5+

← Belnacasan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Oct 11 2022	Wortmann et al., NCT05164120	A Proof of Concept, Randomized, Double-blind, Placebo-controlled Trial of Orally Administered Belnacasan Tablets for the Treatment of Mild to Moderate COVID-19
Oct 11 2022	34% slower recovery (p=0.29). RCT 40 outpatients in the USA, showing no significant difference in recovery with belnacasan treatment.